Arvinas Inc (NASDAQ:ARVN) CFO Sean A. Cassidy sold 1,514 shares of Arvinas stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $37.61, for a total transaction of $56,941.54. Following the sale, the chief financial officer now owns 153,906 shares in the company, valued at $5,788,404.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Arvinas stock opened at $40.82 on Thursday. The company has a current ratio of 8.86, a quick ratio of 8.86 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $46.71 and its two-hundred day moving average price is $36.47. Arvinas Inc has a 52 week low of $14.06 and a 52 week high of $54.95. The stock has a market cap of $1.48 billion, a PE ratio of -19.35 and a beta of 2.44.
Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.02). Arvinas had a negative return on equity of 30.16% and a negative net margin of 163.56%. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $4.77 million. On average, equities analysts predict that Arvinas Inc will post -2.47 EPS for the current fiscal year.
ARVN has been the topic of a number of recent analyst reports. Piper Jaffray Companies lifted their price objective on shares of Arvinas from $35.00 to $58.00 and gave the company an “overweight” rating in a research note on Monday, January 6th. HC Wainwright initiated coverage on shares of Arvinas in a research note on Thursday, December 19th. They set a “buy” rating and a $50.00 price objective on the stock. Wedbush lifted their price objective on shares of Arvinas from $39.00 to $60.00 and gave the company an “outperform” rating in a research note on Friday, January 24th. Piper Sandler restated a “buy” rating and set a $58.00 price objective on shares of Arvinas in a research note on Monday, March 16th. Finally, ValuEngine upgraded shares of Arvinas from a “sell” rating to a “hold” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Arvinas presently has a consensus rating of “Buy” and a consensus target price of $49.55.
Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.